Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo - PubMed (original) (raw)

Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo

L Lefrancois. J Virol. 1984 Jul.

Abstract

Monoclonal antibodies (MAb) reactive with the glycoprotein of vesicular stomatitis virus (VSV) serotypes Indiana (VSV-Ind) and New Jersey (VSV-NJ) were used to protect mice against lethal infection. MAb which reacted with a number of distinct epitopes and which could neutralize the virus in vitro could also protect against infection in vivo. MAb which could not neutralize the virus in vitro but which were specific for the glycoprotein of a single serotype were also able to protect mice against lethal VSV challenge. Interestingly, a group of MAb which cross-reacted with the glycoproteins of VSV-Ind and VSV-NJ could passively protect against challenge with either serotype. It was shown that as early as 2 h after infection, neither neutralizing nor nonneutralizing MAb could protect. Nonneutralizing MAb were found to be less effective at in vivo protection than neutralizing MAb. Furthermore, nonneutralizing MAb demonstrated a much lower binding efficiency to intact virions than did neutralizing MAb. These observations, plus the fact that the nonneutralizing MAb could lyse virus-infected cells in the presence of complement, suggested that in vivo protection by these antibodies may involve cell-associated viral determinants. To compare the mechanisms by which neutralizing and nonneutralizing MAb protected in vivo, F(ab')2 fragments were used in protection experiments. Although the F(ab')2 of a neutralizing MAb was still able to protect animals lethal virus challenge, the F(ab')2 of a cross-reactive nonneutralizing MAb was unable to do so. The reactivity of nonneutralizing MAb with virions and the apparent necessity of an intact Fc portion for protection further distinguish these antibodies from those MAb that are able to neutralize VSV solely by binding to the glycoprotein.

PubMed Disclaimer

Cited by

Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes.
Dharakul T, Rott L, Greenberg HB. Dharakul T, et al. J Virol. 1990 Sep;64(9):4375-82. doi: 10.1128/JVI.64.9.4375-4382.1990. J Virol. 1990. PMID: 1974652 Free PMC article.
Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.
Hangartner L, Zellweger RM, Giobbi M, Weber J, Eschli B, McCoy KD, Harris N, Recher M, Zinkernagel RM, Hengartner H. Hangartner L, et al. J Exp Med. 2006 Aug 7;203(8):2033-42. doi: 10.1084/jem.20051557. Epub 2006 Jul 31. J Exp Med. 2006. PMID: 16880253 Free PMC article.
Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.
Mozdzanowska K, Feng J, Gerhard W. Mozdzanowska K, et al. J Virol. 2003 Aug;77(15):8322-8. doi: 10.1128/jvi.77.15.8322-8328.2003. J Virol. 2003. PMID: 12857901 Free PMC article.
Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.
Scheu S, Alferink J, Pötzel T, Barchet W, Kalinke U, Pfeffer K. Scheu S, et al. J Exp Med. 2002 Jun 17;195(12):1613-24. doi: 10.1084/jem.20020215. J Exp Med. 2002. PMID: 12070288 Free PMC article.
A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.
Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. Mozdzanowska K, et al. J Virol. 1997 Jun;71(6):4347-55. doi: 10.1128/JVI.71.6.4347-4355.1997. J Virol. 1997. PMID: 9151823 Free PMC article.

References

1. N Engl J Med. 1967 Nov 9;277(19):989-94 - PubMed
1. Virology. 1983 Apr 15;126(1):259-66 - PubMed
1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
1. J Neuropathol Exp Neurol. 1971 Apr;30(2):266-77 - PubMed
1. J Virol. 1972 Dec;10(6):1231-5 - PubMed

Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo - PubMed (original) (raw)